Cellectar Biosciences Patent Application for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles Published by USPTO
20 Mai 2016 - 2:30PM
Cellectar Biosciences, Inc. (NASDAQ:CLRB) (the Company), an
oncology-focused biotechnology company, today announces that its
previously filed non-provisional US and International (PCT) patent
applications for Phospholipid-Ether Analogs as Cancer Targeting
Drug Vehicles have received their US Patent and Trademark Office
(USPTO) identification numbers and have been published by the
USPTO, which marks the next step in the application process for
approval and issuance of these patents.
As previously stated, these patents will protect both
composition of matter and method of use for those phospholipid drug
conjugates, or PDCs, developed with Cellectar’s proprietary
phospholipid-ether delivery vehicle conjugated with any existing or
future cytotoxic agents, including chemotherapeutics such as
paclitaxel, for targeted delivery to cancer cells and cancer stem
cells.
“When issued, these patents will provide Cellectar and potential
partners with intellectual property (IP) protection through
approximately November 2036, providing significant runway for
product development and commercialization,” said Jim Caruso,
president and CEO of Cellectar. “This expanded IP protection
supports the value-optimizing potential of our CLR CTX
chemotherapeutic program and we look forward to providing ongoing
updates as we continue to advance this R&D program.”
The objective of the CLR CTX program is to develop PDC
chemotherapeutics through conjugation of the Company’s delivery
vehicle and non-targeted anti-cancer agents to improve therapeutic
indices and expand potential indications through targeted cancer
cell delivery of chemotherapeutic payloads.
About Phospholipid Drug Conjugates (PDCs)
Cellectar's PDC platform has demonstrated highly selective
cancer targeting both preclinically in over 60 in vivo cancer
models, and subsequently confirmed clinically in over 10 cancer
types. The platform's payload diversity has been validated using
cytotoxic radioisotopes for cancer therapy; PET imaging isotopes
for cancer imaging; fluorophores for image-guided surgery, and now
the company plans to expand its payload portfolio to
chemotherapeutics with further preclinical study of paclitaxel and
other non-targeted anti-cancer agents with both in-house and
collaborative R&D efforts.
About Cellectar Biosciences, Inc. Cellectar
Biosciences is developing phospholipid drug conjugates (PDCs)
designed to provide cancer targeted delivery of diverse oncologic
payloads to a broad range of cancers and cancer stem cells.
Cellectar's PDC Delivery Platform is based on the company's
proprietary phospholipid ether analogs. These novel small-molecules
have demonstrated highly selective uptake and retention in a broad
range of cancers. Cellectar's PDC pipeline includes product
candidates for cancer therapy and cancer diagnostic imaging. The
company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a
cytotoxic radioisotope, as its payload. CLR 131 is currently being
evaluated under an orphan drug designated Phase 1 study in patients
with relapsed or refractory multiple myeloma. The company is also
developing PDCs for targeted delivery of chemotherapeutics such as
paclitaxel (CLR 1602-PTX), a preclinical stage product candidate,
and plans to expand its PDC chemotherapeutic pipeline through both
in-house and collaborative R&D efforts. For additional
information please visit www.cellectarbiosciences.com.
This news release contains forward-looking statements. You can
identify these statements by our use of words such as "may,"
"expect," "believe," "anticipate," "intend," "could," "estimate,"
"continue," "plans," or their negatives or cognates. These
statements are only estimates and predictions and are subject to
known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the
statements made. These statements are based on our current beliefs
and expectations as to such future outcomes. Drug discovery and
development involve a high degree of risk. Factors that might cause
such a material difference include, among others, uncertainties
related to the ability to raise additional capital, uncertainties
related to the ability to attract and retain partners for our
technologies, the identification of lead compounds, the successful
preclinical development thereof, the completion of clinical trials,
the FDA review process and other government regulation, our
pharmaceutical collaborators' ability to successfully develop and
commercialize drug candidates, competition from other
pharmaceutical companies, product pricing and third-party
reimbursement. A complete description of risks and uncertainties
related to our business is contained in our periodic reports filed
with the Securities and Exchange Commission including our Form 10-K
for the year ended December 31, 2015. These forward-looking
statements are made only as of the date hereof, and we disclaim any
obligation to update any such forward-looking statements.
INVESTOR AND MEDIA CONTACT:
Jules Abraham
JQA Partners
917-885-7378
jabraham@jqapartners.com
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jul 2023 bis Jul 2024